Clinical Scenario: Implementation of Bispecific Therapy for Relapsed Refractory Multiple Myeloma in a Community Center
Panelists discuss how community centers can effectively implement bispecific antibody therapy for patients with relapsed/refractory multiple myeloma, addressing challenges such as staff training, patient monitoring, and managing potential adverse events in a non-academic setting.
EP: 1.Talquetamab, a GPRC5DxCD3 bispecific antibody (BsAb), for Relapsed Refractory Multiple Myeloma: MonumenTAL-1 Data and Implications
EP: 2.Bispecific Antibody Combinations In Relapsed Refractory Multiple Myeloma: TRIMM-2 Study
EP: 3.Bispecific Antibody Combinations In Relapsed Refractory Multiple Myeloma: RedirecTT-1 Follow-Up
EP: 4.Prophylactic Tocilizumab in MajesTEC-1 for the Reduction of CRS
EP: 5.OPTec: Outpatient Step Up Administration of Teclistamab: Implications in Real-World Practice
EP: 6.Sequencing Therapies in Relapsed Refractory Multiple Myeloma: Bispecifics and CAR T-Cell Therapies
EP: 7.Dosing Interval and Considerations for Bispecifics Combination in Relapsed Refractory Multiple Myeloma
EP: 8.Clinical Scenario: A 58-Year Old Woman with Relapsed Refractory Mutiple Myeloma, post-ASCT, MRD-negative, on Bispecific Therapy
Now Viewing
EP: 9.Clinical Scenario: Implementation of Bispecific Therapy for Relapsed Refractory Multiple Myeloma in a Community Center
EP: 10.Experts Discuss Choosing Bispecifics and Sequencing Options in Multiple Myeloma
Related Content
Fostering Academic, Community Practice Collaboration for Bispecific Therapy in Multiple Myeloma
December 26th 2024Article
Experts in multiple myeloma spoke about optimal treatment strategies for patients who receive bispecific therapy, focusing specifically on facilitating a multifaceted approach between academic and community practices.
